Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$174.72 USD

174.72
8,241,747

+0.30 (0.17%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $175.51 +0.79 (0.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Equity Research

AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals

AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.

Zacks Equity Research

Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?

Smart Beta ETF report for DGRO

Zacks Equity Research

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

Smart Beta ETF report for VYM

Zacks Equity Research

Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues

Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.

Zacks Equity Research

Should iShares S&P 500 Value ETF (IVE) Be on Your Investing Radar?

Style Box ETF report for IVE

Zacks Equity Research

Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?

Smart Beta ETF report for DGRW

Zacks Equity Research

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1

Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.

Zacks Equity Research

J&J (JNJ) Updates COVID Jab Label to Include Blood Clot Risk

J&J's (JNJ) decision to update the label of its COVID-19 vaccine came on the heels of the FDA's decision to limit the authorized use of its vaccine due to the risk of TTS.

Zacks Equity Research

Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?

Smart Beta ETF report for PWV

Zacks Equity Research

Should Vanguard S&P 500 Value ETF (VOOV) Be on Your Investing Radar?

Style Box ETF report for VOOV

Zacks Equity Research

Is iShares Core S&P U.S. Value ETF (IUSV) a Strong ETF Right Now?

Smart Beta ETF report for IUSV

Zacks Equity Research

Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?

Style Box ETF report for MGV

Zacks Equity Research

Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates

Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.

Zacks Equity Research

AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica

AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.

Zacks Equity Research

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN

Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.

Zacks Equity Research

Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?

Style Box ETF report for QUS